Eikon’s EIK1001 Advances into Registrational Studies; Price Target Remains $23
at www.tipranks.com (Thu, 12-Nov 10:35 AM)
Eikon Therapeutics, Inc. reports Q3 results
at seekingalpha.com (Thu, 12-Nov 6:43 AM)
Eikon Therapeutics to Spotlight PARP Inhibitor Advances at Cantor Fitzgerald KOL Event
Market Chameleon (Wed, 19-Aug 11:07 AM)
Eikon Therapeutics to Share Insights on PARP Inhibitors in Oncology at Cantor Fitzgerald KOL Event
Market Chameleon (Wed, 19-Aug 8:11 AM)
